Targeting the Skp2–Cks1 protein–protein interaction: structures, assays, and preclinical inhibitors
European Journal of Pharmacology · 2025
DOI: 10.1016/j.ejphar.2025.178129 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Pharmacology, 2025. Verfasst von Emadeldin M Kamel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, 62514, Egypt. Electronic address: emad.abdelhameed@science.bsu.edu.eg. Hauptthemen laut MEDLINE: S-Phase Kinase-Associated Proteins, CDC2-CDC28 Kinases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Deanship of Scientific Research, Imam Mohammed Ibn Saud Islamic University, Imam Mohammed Ibn Saud Islamic University.
Abstract (Originalsprache)
The Skp2-Cks1 protein-protein interaction (PPI) within the SCFSkp2 ubiquitin ligase acts as a co-receptor for phosphorylated CDK inhibitors-most prominently p27Kip1-relieving CDK inhibition and advancing the cell cycle, a dependency accentuated in RB-pathway-defective cancers. Crystallographic and cryo-EM analyses delineate a composite pocket formed by the Skp2 leucine-rich-repeat groove and the phosphate-recognition site of Cks1; Cks1-centered open-closed motions further influence druggability. Using HTRF/TR-FRET and AlphaScreen biochemistry, alongside cell-based target-engagement readouts in some studies, three small-molecule classes have emerged that disrupt this PPI: 1,3-diphenyl-pyrazines and triazolo[1,5-a]pyrimidines (lead E35) with low-micromolar potency, and "Skp2E3LI" compounds with micromolar cellular activity. These agents elevate p27 (and in some reports p21), curb proliferation, and show in-vivo effects in defined models: diphenyl-pyrazines in prostate and gastric xenografts, E35 in gastric xenografts, and Skp2E3LIs in estrogen-driven endometrial hyperplasia. Additional strategies that impinge on the Skp2 axis-such as SKPin-C1 or neddylation blockade-suppress osteosarcoma and small-cell lung cancer models; doxorubicin combinations are synergistic in osteosarcoma, whereas neddylation combinations yield enhanced but not uniformly synergistic activity. Genetic validation comes from a Cks1N45R knock-in that prevents Skp2-Cks1 binding, stabilizes p27, and phenocopies Skp2 loss without systemic lethality. Key needs include pushing potency into the sub-micromolar range, broad selectivity profiling, and defining long-term safety in proliferative tissues, with biomarker-guided development focused on RB1 loss, SKP2 overexpression, and nuclear p27 depletion. Degrader approaches (PROTACs/molecular glues) remain preclinical. This review synthesizes these advances and outlines priorities for translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, 62514, Egypt. Electronic address: emad.abdelhameed@science.bsu.edu.eg.
- Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 11623, Saudi Arabia.
- Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, P.O. Box 62521, Beni-Suef, Egypt.
- Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, 51452, Saudi Arabia.
- Departamento de Química and Institute for Advanced Research in Chemical Science (IAdChem), Facultad de Ciencias, Módulo 13, Universidad Autónoma de Madrid, 28049, Madrid, Spain.
Förderung
- Deanship of Scientific Research, Imam Mohammed Ibn Saud Islamic University
- Imam Mohammed Ibn Saud Islamic University
Zitieren
APA
Kamel, E. M., Khadrawy, S. M., Allam, A. A., Ahmed, N. A., Aba Alkhayl, F. F., & Lamsabhi, A. M. (2025). Targeting the Skp2–Cks1 protein–protein interaction: structures, assays, and preclinical inhibitors. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.178129
Vancouver
Kamel EM, Khadrawy SM, Allam AA, Ahmed NA, Aba Alkhayl FF, Lamsabhi AM. Targeting the Skp2–Cks1 protein–protein interaction: structures, assays, and preclinical inhibitors. European Journal of Pharmacology. 2025. doi:10.1016/j.ejphar.2025.178129
BibTeX
@article{Kamel2025,
author = {Kamel, Emadeldin M and Khadrawy, Sally Mostafa and Allam, Ahmed A and Ahmed, Noha A and Aba Alkhayl, Faris F and Lamsabhi, Al Mokhtar},
title = {Targeting the Skp2–Cks1 protein–protein interaction: structures, assays, and preclinical inhibitors},
journal = {European Journal of Pharmacology},
year = {2025},
doi = {10.1016/j.ejphar.2025.178129}
}
EUVIMED